Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome

• Verfasst von: Scheer, Carina [VerfasserIn]
• Verfasst von: Witt, Olaf [VerfasserIn]
• Titel: Hematologic response to vorinostat treatment in relapsed myeloid leukemia of Down syndrome
• Verf.angabe: Carina Scheer, Christian Kratz, Olaf Witt, Ursula Creutzig, Dirk Reinhardt, and Jan-Henning Klusmann
• Umfang: 3 S.
• Fussnoten: Gesehen am 01.03.2018
• Titel Quelle: Enthalten in: Pediatric blood & cancer
• Jahr Quelle: 2016
• Band/Heft Quelle: 63(2016), 9, S. 1677-1679
• ISSN Quelle: 1545-5017
• DOI: doi:10.1002/pbc.26062
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1570331790

Abstract

Children with Down syndrome are at high risk to develop myeloid leukemia (ML-DS). Despite their excellent prognosis, children with ML-DS particularly suffer from severe therapy-related toxicities and for relapsed ML-DS the cure rates are very poor. Here we report the clinical course of one child with ML-DS treated with the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid) after second relapse. The child had previously received conventional chemotherapy and stem cell transplantation, yet showed a remarkable clinical and hematologic response. Thus, HDAC inhibitor may represent an effective class of drugs for the treatment of ML-DS.